Robert W. Baird Raises LivaNova (NASDAQ:LIVN) Price Target to $66.00

LivaNova (NASDAQ:LIVN - Free Report) had its price target upped by Robert W. Baird from $58.00 to $66.00 in a report issued on Thursday, Benzinga reports. Robert W. Baird currently has a neutral rating on the stock.

Other equities research analysts have also recently issued reports about the stock. Needham & Company LLC reissued a buy rating and issued a $72.00 target price on shares of LivaNova in a research report on Wednesday. Mizuho raised their target price on shares of LivaNova from $75.00 to $80.00 and gave the stock a buy rating in a research report on Thursday. StockNews.com raised shares of LivaNova from a hold rating to a buy rating in a research report on Thursday, April 25th. Finally, Barclays lifted their price target on shares of LivaNova from $57.00 to $61.00 and gave the company an equal weight rating in a research report on Monday, February 26th. Three investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat, the company has an average rating of Moderate Buy and an average target price of $66.20.

LivaNova Trading Up 0.5 %

Shares of LivaNova stock traded up $0.30 during mid-day trading on Thursday, hitting $62.92. 1,500,572 shares of the stock were exchanged, compared to its average volume of 648,706. LivaNova has a twelve month low of $42.75 and a twelve month high of $63.21. The stock has a market capitalization of $3.41 billion, a price-to-earnings ratio of 196.63 and a beta of 0.92. The company has a 50-day simple moving average of $54.57 and a 200 day simple moving average of $50.94. The company has a current ratio of 2.95, a quick ratio of 2.51 and a debt-to-equity ratio of 0.44.

LivaNova (NASDAQ:LIVN - Get Free Report) last released its quarterly earnings results on Wednesday, May 1st. The company reported $0.73 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.45 by $0.28. LivaNova had a net margin of 1.53% and a return on equity of 12.23%. The company had revenue of $294.90 million for the quarter, compared to analysts' expectations of $278.17 million. During the same period last year, the company earned $0.43 EPS. The firm's revenue for the quarter was up 12.0% compared to the same quarter last year. Research analysts forecast that LivaNova will post 3.01 EPS for the current year.

Institutional Trading of LivaNova

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Norges Bank acquired a new position in LivaNova in the fourth quarter worth $26,064,000. Ameriprise Financial Inc. boosted its holdings in shares of LivaNova by 96.1% during the third quarter. Ameriprise Financial Inc. now owns 916,632 shares of the company's stock valued at $48,471,000 after acquiring an additional 449,136 shares during the period. Primecap Management Co. CA boosted its holdings in shares of LivaNova by 7.3% during the third quarter. Primecap Management Co. CA now owns 5,785,360 shares of the company's stock valued at $305,930,000 after acquiring an additional 395,940 shares during the period. Loomis Sayles & Co. L P boosted its holdings in shares of LivaNova by 31.1% during the third quarter. Loomis Sayles & Co. L P now owns 879,740 shares of the company's stock valued at $46,520,000 after acquiring an additional 208,755 shares during the period. Finally, Healthcare of Ontario Pension Plan Trust Fund acquired a new position in shares of LivaNova during the fourth quarter valued at $8,330,000. Institutional investors own 97.64% of the company's stock.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.